Novartis tries to block generic versions of Gilenya, enforces new patent

Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis accused of owing $47m in IP royalties

15 July 2021 Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.

Big Pharma

Novartis secures victory as MS drug patent is upheld

18 August 2020 In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.

Big Pharma

UKIPO rejects Novartis’s TM opposition attempt

18 June 2020 Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Novartis tries to block generic versions of Gilenya, enforces new patent

More on this story

Editor's picks

Editor's picks

More features